Arrowstreet Capital
ANIK icon

Arrowstreet Capital’s Anika Therapeutics ANIK Stock Holding History

Arrowstreet Capital’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
106,644
+75,290
+240% +$1.12M ﹤0.01% 1570
2026
Q1 		$455K Sell
31,354
-21,640
-41% -$251K ﹤0.01% 1686
2025
Q4 		$509K Hold
52,994
– – ﹤0.01% 1677
2025
Q3 		$498K Hold
52,994
– – ﹤0.01% 1702
2025
Q2 		$561K Sell
52,994
-5,601
-10% -$70.7K ﹤0.01% 1730
2025
Q1 		$881K Sell
58,595
-860
-1% -$14.3K ﹤0.01% 1497
2024
Q4 		$979K Sell
59,455
-49,338
-45% -$973K ﹤0.01% 1463
2024
Q3 		$2.69M Hold
108,793
– – ﹤0.01% 1153
2024
Q2 		$2.76M Sell
108,793
-11,026
-9% -$286K ﹤0.01% 993
2024
Q1 		$3.04M Sell
119,819
-102,691
-46% -$2.48M ﹤0.01% 1031
2023
Q4 		$5.04M Buy
222,510
+83,396
+60% +$1.73M 0.01% 748
2023
Q3 		$2.59M Buy
+139,114
New +$2.89M ﹤0.01% 797
2022
Q1 		– Sell
-29,906
Closed -$1.07M – 1176
2021
Q4 		$1.07M Buy
29,906
+210
+0.7% +$8.41K ﹤0.01% 1151
2021
Q3 		$1.26M Sell
29,696
-20,365
-41% -$839K ﹤0.01% 1242
2021
Q2 		$2.17M Buy
+50,061
New +$2.13M ﹤0.01% 1327
2020
Q3 		– Sell
-47,155
Closed -$1.78M – 2311
2020
Q2 		$1.78M Sell
47,155
-30,835
-40% -$1.02M ﹤0.01% 1532
2020
Q1 		$2.25M Sell
77,990
-129,070
-62% -$5.22M 0.01% 1022
2019
Q4 		$10.7M Buy
207,060
+124,973
+152% +$7.26M 0.03% 592
2019
Q3 		$4.51M Buy
82,087
+3,224
+4% +$166K 0.01% 736
2019
Q2 		$3.2M Buy
78,863
+19,300
+32% +$704K 0.01% 781
2019
Q1 		$1.8M Buy
+59,563
New +$2.04M ﹤0.01% 1142
2016
Q4 		– Sell
-26,721
Closed -$1.28M – 1624
2016
Q3 		$1.28M Buy
+26,721
New +$1.32M ﹤0.01% 1020
2014
Q4 		– Sell
-17,236
Closed -$632K – 1219
2014
Q3 		$632K Sell
17,236
-24,303
-59% -$1.05M ﹤0.01% 795
2014
Q2 		$1.93M Buy
41,539
+30,737
+285% +$1.37M 0.01% 599
2014
Q1 		$444K Buy
+10,802
New +$402K ﹤0.01% 979

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital's ANIK Position: Q2 2026 in Review

Arrowstreet Capital increased its Anika Therapeutics (ANIK) stake by 240% in Q2 2026, buying an estimated $1.12M and bringing the position to 106,644 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #1570.

Arrowstreet Capital first reported a position in ANIK in Q1 2014 and has held it in 25 quarters since. The position peaked at $10.7M in Q4 2019. 89 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Arrowstreet Capital held 106,644 shares of Anika Therapeutics worth $1.56M as of Q2 2026.
  • Arrowstreet Capital bought 75,290 Anika Therapeutics shares in Q2 2026, an estimated $1.12M.
  • Anika Therapeutics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1570 holding.
  • Arrowstreet Capital first reported a position in Anika Therapeutics in Q1 2014 and has held it in 25 quarters since.
  • Arrowstreet Capital's Anika Therapeutics position peaked at $10.7M in Q4 2019.
  • 89 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.